Quick Answer
TScan Therapeutics, Inc. reported Total Revenue of $10.32 million for fiscal year 2025.
TScan Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $10.32M | +266.7% |
| 2024 | $2.82M | -86.6% |
| 2023 | $21.05M | +55.5% |
| 2022 | $13.54M | +33.5% |
| 2021 | $10.14M | +834.7% |
| 2020 | $1.08M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.51M | +139.4% | -18.4% |
| June 30, 2025 | $3.08M | +473.9% | +41.7% |
| March 31, 2025 | $2.17M | +283.6% | +107.0% |
| September 30, 2024 | $1.05M | -73.0% | +95.7% |
| June 30, 2024 | $536.0K | -83.0% | -5.3% |
| March 31, 2024 | $566.0K | -91.7% | -85.4% |
| September 30, 2023 | $3.89M | +15.6% | +23.5% |
| June 30, 2023 | $3.15M | -22.4% | -53.7% |
- TScan Therapeutics, Inc. showed an increase of +266.7% in Total Revenue compared to the prior fiscal year.
- Over the 2020–2025 period, TScan Therapeutics, Inc.’s total revenue has grown by 851.6% (from $1.08 million to $10.32 million).
- The most recent figure is from TScan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: